

**Supplementary Table 1.** Exposure time (days) of individual drugs in different drug classes

Variable	Cohort 1	
	Number	Mean $\pm$ SD
Cohort 1		
SGLT2i		
Dapagliflozin	16,989	268.0 $\pm$ 214.8
Empagliflozin	2,362	77.3 $\pm$ 59.9
Ipragliflozin	2,337	127.6 $\pm$ 115.6
DPP-4i		
Alogliptin	3,242	290.0 $\pm$ 234.2
Anagliptin	897	195.2 $\pm$ 125.1
Evogliptin	697	133.7 $\pm$ 88.9
Gemigliptin	3,759	248.5 $\pm$ 211.6
Linagliptin	5,032	278.5 $\pm$ 230.5
Saxagliptin	1,020	283.2 $\pm$ 225.6
Sitagliptin	4,084	272.7 $\pm$ 229.4
Teneligliptin	1,838	203.6 $\pm$ 143.1
Vildagliptin	1,119	267.2 $\pm$ 229.2
Cohort 2		
SGLT2i		
Dapagliflozin	15,872	272.1 $\pm$ 217.9
Empagliflozin	2,118	76.2 $\pm$ 59.5
Ipragliflozin	2,130	127.5 $\pm$ 117.1
SU		
Glibenclamide	66	225.4 $\pm$ 239.0
Gliclazide	1,819	206.4 $\pm$ 204.0
Glimepiride	18,215	202.8 $\pm$ 202.2
Glipizide	20	182.8 $\pm$ 147.9

SD, standard deviation; SGLT2i, sodium glucose cotransporter 2 inhibitor; DPP-4i, dipeptidyl peptidase-4 inhibitor; SU, sulfonylurea.